Aspen Aerogels, Inc. (ASPN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ASPN SEC filings page.
Aspen Aerogels, Inc. (ASPN) reported $202.1M in revenue over the twelve months to Jun 30, 2026, down 49.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Aspen’s 2025 reported profitability collapse was not matched by operating cash outflow, while capital spending still exceeded cash generated.
FY2025 paired a net loss of$389.6M with operating cash flow of$32.9M , a mismatch indicating substantial noncash effects. That differs from FY2024, when net income of$13.4M and operating cash flow of$45.5M aligned more closely, making the latest loss a poor standalone measure of cash deterioration.
Revenue fell from
Capital spending declined from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aspen Aerogels, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aspen Aerogels, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 13/100.
Aspen Aerogels, Inc.'s revenue declined 40.1% year-over-year, from $452.7M to $271.1M. This contraction results in a growth score of 56/100.
Aspen Aerogels, Inc. carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 71/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.90, Aspen Aerogels, Inc. holds $3.90 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.
While Aspen Aerogels, Inc. generated $32.9M in operating cash flow, capex of $37.4M consumed most of it, leaving -$4.6M in free cash flow. This results in a low score of 8/100, reflecting heavy capital investment rather than weak cash generation.
Aspen Aerogels, Inc. posts a -165.4% return on equity (ROE), meaning it loses $165 for every $100 of shareholders' equity. This results in a returns score of 11/100. This is down from 2.2% the prior year.
Aspen Aerogels, Inc. scores -3.85, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($467.2M) relative to total liabilities ($171.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aspen Aerogels, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Aspen Aerogels, Inc. reported a net loss of $389.6M while generating $32.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Aspen Aerogels, Inc. reported an operating loss of $378.2M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Aspen Aerogels, Inc. generated $49.8M in revenue in Q2 2026. This represents a decrease of 36.1% from the same quarter a year earlier. Against the prior quarter it is up 31.6%.
Aspen Aerogels, Inc.'s EBITDA was -$24.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3921.1% from the same quarter a year earlier. Against the prior quarter it is down 58.5%.
Aspen Aerogels, Inc. reported -$23.3M in net income in Q2 2026. This represents a decrease of 156.9% from the same quarter a year earlier. Against the prior quarter it is up 1.8%.
Aspen Aerogels, Inc. earned -$0.28 per diluted share (EPS) in Q2 2026. This represents a decrease of 154.5% from the same quarter a year earlier. Against the prior quarter it is up 3.4%.
Cash & Balance Sheet
Aspen Aerogels, Inc. recorded an outflow of $18.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 7.1% from the same quarter a year earlier. Against the prior quarter it is down 154.9%.
Aspen Aerogels, Inc. held $151.7M in cash against $57.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Aspen Aerogels, Inc.'s gross margin was 6.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 25.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.7 percentage points.
Aspen Aerogels, Inc.'s operating margin was -57.7% in Q2 2026, reflecting core business profitability. This is down 51.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.
Aspen Aerogels, Inc.'s net profit margin was -46.7% in Q2 2026, showing the share of revenue converted to profit. This is down 35.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 15.9 percentage points.
Aspen Aerogels, Inc.'s ROE was -12.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 9.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.
Capital Allocation
Aspen Aerogels, Inc. invested $3.2M in research and development in Q2 2026. This represents a decrease of 15.8% from the same quarter a year earlier. Against the prior quarter it is up 17.3%.
Aspen Aerogels, Inc. invested $1.8M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 86.0% from the same quarter a year earlier. Against the prior quarter it is up 31.8%.
Not reported for Q2 2026.
ASPN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M-36.1% | $37.9M-51.9% | $41.3M-66.4% | $73.0M-37.8% | $78.0M-33.7% | $78.7M-16.7% | $123.1M+46.2% | $117.3M+93.1% |
| Cost of Revenue | $46.6M-11.6% | $33.6M-39.9% | $64.3M-15.4% | $52.2M-23.5% | $52.7M-20.4% | $55.9M-5.8% | $76.0M+39.1% | $68.3M+45.5% |
| Gross Profit | $3.3M-87.1% | $4.3M-81.3% | -$22.9M-148.6% | $20.8M-57.6% | $25.3M-50.9% | $22.8M-35.1% | $47.1M+59.1% | $49.0M+255.1% |
| R&D Expenses | $3.2M-15.8% | $2.7M-37.1% | $2.8M-36.5% | $2.5M-45.7% | $3.8M-16.9% | $4.3M-3.5% | $4.4M+8.1% | $4.6M+8.8% |
| SG&A Expenses | $13.0M-6.2% | $15.3M+17.3% | $15.4M-17.6% | $13.5M-23.7% | $13.8M-21.0% | $13.0M-24.3% | $18.7M+21.3% | $17.7M+12.0% |
| Operating Income | -$28.8M-458.4% | -$20.8M+93.0% | -$70.4M-578.4% | -$3.3M-119.2% | -$5.2M-125.8% | -$299.3M-12388.2% | $14.7M+963.8% | $17.4M+218.9% |
| EBITDA | -$24.5M-3921.1% | -$15.5M+94.7% | -$42.2M-309.5% | $2.0M-91.0% | $641K-97.5% | -$293.5M-3670.3% | $20.1M+238.9% | $22.7M+325.3% |
| Interest Expense | $2.8M-9.9% | $3.2M+60.6% | $2.7M | $3.0M+159.2% | $3.1M | $2.0M+311.3% | N/A | $1.1M |
| Income Tax | $619K-24.6% | -$253K-123.5% | -$97K+44.6% | $594K+122.5% | $821K-5.2% | $1.1M+42.3% | -$175K | $267K |
| Net Income | -$23.3M-156.9% | -$23.7M+92.1% | -$72.9M-741.7% | -$6.3M+51.2% | -$9.1M-153.8% | -$301.2M-16316.8% | $11.4M+2289.2% | -$13.0M+0.8% |
| EPS (Basic) | -$0.28-154.5% | -$0.29+92.1% | -$0.88-728.6% | -$0.08+52.9% | -$0.11-150.0% | -$3.67-18250.0% | $0.14+1500.0% | -$0.17+10.5% |
| EPS (Diluted) | -$0.28-154.5% | -$0.29+92.1% | -$0.88-728.6% | -$0.08+52.9% | -$0.11-152.4% | -$3.67-18250.0% | $0.14 | -$0.17+10.5% |
| Diluted Shares (Avg) | 83M+0.9% | 83M+0.8% | N/A | 82M+8.0% | 82M+4.0% | 82M+8.3% | N/A | 76M+10.0% |
ASPN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $392.9M-25.2% | $410.5M-26.0% | $406.7M-54.6% | $491.4M-37.2% | $525.1M-29.9% | $555.0M-20.5% | $895.1M+27.3% | $782.6M+29.3% |
| Current Assets | $248.5M-20.0% | $254.0M-26.1% | $242.1M-40.9% | $278.9M-8.8% | $310.5M+7.6% | $343.9M+34.8% | $409.4M+53.7% | $305.9M+52.6% |
| Cash & Equivalents | $151.7M-9.5% | $173.9M-9.5% | $156.9M-29.0% | $150.7M+32.8% | $167.6M+83.4% | $192.0M+89.3% | $220.9M+58.1% | $113.5M+19.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $27.9M-46.4% | $31.1M-45.3% | $38.2M-19.6% | $43.0M-9.3% | $52.1M-1.7% | $56.7M+24.0% | $47.6M+21.3% | $47.4M+37.8% |
| Accounts Receivable | $40.3M-47.1% | $36.4M-52.9% | $35.3M-67.7% | $69.1M-40.0% | $76.2M-34.9% | $77.4M-7.9% | $109.1M+55.9% | $115.2M+111.7% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $200.5M-7.3% | $197.0M-18.0% | $171.2M-39.0% | $185.7M-32.5% | $216.4M-6.3% | $240.1M+16.1% | $280.4M+30.4% | $274.9M+40.8% |
| Current Liabilities | $98.6M+26.4% | $87.8M+7.8% | $62.0M-43.7% | $70.7M-32.2% | $78.0M-6.5% | $81.4M+28.1% | $110.1M+41.0% | $104.3M+70.3% |
| Non-Current Liabilities | $101.8M-26.4% | $109.2M-31.2% | $109.1M-35.9% | $114.9M-32.7% | $138.3M-6.1% | $158.7M+10.8% | $170.3M+24.4% | $170.6M+27.3% |
| Long-Term Debt | $57.0M-26.3% | $61.2M-35.8% | $65.5M-31.1% | $70.1M-25.2% | $77.3M | $95.4M | $95.0M | $93.7M |
| Total Equity | $192.5M-37.7% | $213.5M-32.2% | $235.5M-61.7% | $305.7M-39.8% | $308.8M-40.4% | $314.8M-35.9% | $614.7M+25.9% | $507.6M+23.9% |
| Retained Earnings | -$1.1B-13.0% | -$1.1B-11.6% | -$1.0B-59.0% | -$976.9M-45.5% | -$970.5M-47.4% | -$961.5M-42.3% | -$660.2M+2.0% | -$671.6M+0.2% |
Not reported in any period shown, so not listed: Goodwill.
ASPN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.2M-312.2% | $34.1M+506.3% | $16.1M-54.8% | $15.0M-27.6% | -$3.9M-157.4% | $5.6M+131.7% | $35.7M+1384.1% | $20.8M+376.9% |
| Depreciation & Amortization | $4.3M-26.0% | $5.4M-7.1% | $28.2M+418.6% | $5.4M+1.3% | $5.8M-3.2% | $5.8M+0.1% | $5.4M+19.1% | $5.3M+16.9% |
| Stock-Based Compensation | $3.7M+14.9% | $1.9M-4.4% | N/A | $2.6M+0.5% | $3.2M+8.1% | $2.0M-58.5% | N/A | $2.6M-5.7% |
| Capital Expenditures | $1.8M-86.0% | $1.4M-89.5% | $2.5M-83.3% | $9.1M-56.3% | $12.9M-48.1% | $13.0M-49.7% | $14.8M-46.9% | $20.8M-35.5% |
| Free Cash Flow | -$18.0M-7.1% | $32.8M+545.0% | $13.7M-34.7% | $5.9M+11966.0% | -$16.8M+6.5% | -$7.4M+83.1% | $20.9M+168.5% | -$50K+99.9% |
| Investing Cash Flow | -$1.8M+86.0% | -$1.4M+89.5% | -$2.5M+83.3% | -$9.1M+56.3% | -$12.9M+48.1% | -$13.0M+49.7% | -$14.8M+46.9% | -$20.8M+35.5% |
| Financing Cash Flow | -$4.2M+45.2% | -$15.8M+26.6% | -$7.5M-108.7% | -$21.5M-197.2% | -$7.6M-193.2% | -$21.5M-508.4% | $86.5M+14.4% | $22.2M+17485.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ASPN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 6.6%-25.9pp | 11.3%-17.7pp | -55.5%-93.8pp | 28.5%-13.3pp | 32.5%-11.3pp | 29.0%-8.2pp | 38.3%+3.1pp | 41.8%+19.1pp |
| Operating Margin | -57.7%-51.1pp | -55.0% | -170.3% | -4.6%-19.4pp | -6.6%-23.6pp | -380.3% | 11.9%+10.3pp | 14.8%+38.9pp |
| Net Margin | -46.7%-35.1pp | -62.5% | -176.4% | -8.7%+2.4pp | -11.6%-25.9pp | -382.7% | 9.2%+9.8pp | -11.1%+10.5pp |
| Return on Equity | -12.1%-9.2pp | -11.1%+84.6pp | -31.0%-32.8pp | -2.1%+0.5pp | -2.9%-6.2pp | -95.7%-95.3pp | 1.8%+2.0pp | -2.5%+0.6pp |
| Return on Assets | -5.9%-4.2pp | -5.8%+48.5pp | -17.9%-19.2pp | -1.3%+0.4pp | -1.7%-4.0pp | -54.3%-54.0pp | 1.3%+1.3pp | -1.7%+0.5pp |
| Current Ratio | 2.52-1.5x | 2.89-1.3x | 3.90+0.2x | 3.94+1.0x | 3.98+0.5x | 4.22+0.2x | 3.72+0.3x | 2.93-0.3x |
| Debt-to-Equity | 0.300.0x | 0.290.0x | 0.28+0.1x | 0.230.0x | 0.25-0.2x | 0.30-0.1x | 0.15-0.3x | 0.18-0.3x |
| Asset Turnover | 0.130.0x | 0.090.0x | 0.100.0x | 0.150.0x | 0.150.0x | 0.140.0x | 0.140.0x | 0.150.0x |
| FCF Margin | -36.1%-14.6pp | 86.5%+95.9pp | 33.1%+16.1pp | 8.1%+8.2pp | -21.6%-6.3pp | -9.4%+36.8pp | 17.0%+53.3pp | 0.0%+65.4pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Aspen Aerogels, Inc. ASPN | FY2025 | $271.1M | -$389.6M | N/A | $467.2M | 41/100 |
| JELD-WEN Holding, Inc. JELD | FY2025 | $3.2B | -$621.2M | -19.4% | $153.6M | 19/100 |
| Quanex Building Products Corporation NX | FY2025 | $1.8B | -$250.8M | -13.7% | $842.7M | 50/100 |
| Latham Group, Inc. SWIM | FY2025 | $545.9M | $11.1M | 2.0% | $749.4M | 44/100 |
| Apogee Enterprises Inc APOG | FY2026 | $1.4B | $54.1M | 3.9% | $859.0M | 50/100 |
| Janus International Group, Inc. JBI | FY2025 | $884.2M | $53.8M | 6.1% | $574.4M | 59/100 |
Where Aspen Aerogels, Inc. Ranks
Frequently Asked Questions
What is Aspen Aerogels, Inc.'s annual revenue?
Aspen Aerogels, Inc. (ASPN) reported $271.1M in total revenue for fiscal year 2025. This represents a -40.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aspen Aerogels, Inc.'s revenue growing?
Aspen Aerogels, Inc. (ASPN) revenue declined by 40.1% year-over-year, from $452.7M to $271.1M in fiscal year 2025.
Is Aspen Aerogels, Inc. profitable?
No, Aspen Aerogels, Inc. (ASPN) reported a net income of -$389.6M in fiscal year 2025.
What is Aspen Aerogels, Inc.'s EBITDA?
Aspen Aerogels, Inc. (ASPN) had EBITDA of -$333.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Aspen Aerogels, Inc. have?
As of fiscal year 2025, Aspen Aerogels, Inc. (ASPN) had $156.9M in cash and equivalents against $65.5M in long-term debt.
What is Aspen Aerogels, Inc.'s gross margin?
Aspen Aerogels, Inc. (ASPN) had a gross margin of 17.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Aspen Aerogels, Inc.'s return on equity (ROE)?
Aspen Aerogels, Inc. (ASPN) has a return on equity of -165.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aspen Aerogels, Inc.'s free cash flow?
Aspen Aerogels, Inc. (ASPN) recorded an outflow of $4.6M in free cash flow during fiscal year 2025. This represents a 88.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aspen Aerogels, Inc.'s operating cash flow?
Aspen Aerogels, Inc. (ASPN) generated $32.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aspen Aerogels, Inc.'s total assets?
Aspen Aerogels, Inc. (ASPN) had $406.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aspen Aerogels, Inc.'s capital expenditures?
Aspen Aerogels, Inc. (ASPN) invested $37.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aspen Aerogels, Inc. spend on research and development?
Aspen Aerogels, Inc. (ASPN) invested $13.4M in research and development during fiscal year 2025.
What is Aspen Aerogels, Inc.'s current ratio?
Aspen Aerogels, Inc. (ASPN) had a current ratio of 3.90 as of fiscal year 2025, which is generally considered healthy.
What is Aspen Aerogels, Inc.'s debt-to-equity ratio?
Aspen Aerogels, Inc. (ASPN) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aspen Aerogels, Inc.'s return on assets (ROA)?
Aspen Aerogels, Inc. (ASPN) had a return on assets of -95.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aspen Aerogels, Inc.'s P/E ratio?
Aspen Aerogels, Inc. (ASPN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $467.2M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Aspen Aerogels, Inc.'s price-to-sales ratio?
Aspen Aerogels, Inc. (ASPN) trades at 2.3x sales, its market capitalization divided by revenue of $202.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $467.2M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Aspen Aerogels, Inc.'s Altman Z-Score?
Aspen Aerogels, Inc. (ASPN) has an Altman Z-Score of -3.85, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aspen Aerogels, Inc.'s Piotroski F-Score?
Aspen Aerogels, Inc. (ASPN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aspen Aerogels, Inc.'s earnings high quality?
Aspen Aerogels, Inc. (ASPN) reported a net loss of $389.6M while generating $32.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aspen Aerogels, Inc. cover its interest payments?
Aspen Aerogels, Inc. (ASPN) reported an operating loss of $378.2M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aspen Aerogels, Inc.?
Aspen Aerogels, Inc. (ASPN) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.